ArticleBMC public health2026
Device-measured and self-reported physical activity and the trajectory of cardio-renal-metabolic multimorbidity: a prospective cohort study in UK Biobank.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCardio-renal-metabolic diseases (CRMDs), including cardiovascular disease, chronic kidney disease, and type 2 diabetes, often co-occur and progress from a healthy state to first CRMD (FCRMD), cardio-renal-metabolic multimorbidity (CRMM), and death. We investigated the associations of physical activity (PA), assessed using accelerometer-based and questionnaire-based measures, with the CRMM trajectory.
methodsTwo prospective UK Biobank sub-cohorts free of CRMDs at baseline were analyzed. The accelerometer-based cohort (n = 73,952) provided device-measured light (LPA), moderate (MPA), vigorous (VPA), moderate-to-vigorous (MVPA), and total PA (TPA), whereas the questionnaire-based cohort (n = 328,147) classified self-reported PA as low, moderate, or high. Multi-state models were used to estimate associations between PA and transitions along the CRMM trajectory.
resultsOver median follow-up periods of 7.0 years (accelerometer-based) and 13.6 years (questionnaire-based), 7,303 (9.9%) and 57,389 (17.5%) participants developed FCRMD, respectively. In the accelerometer-based cohort, inverse associations were observed for several transitions originating from baseline or FCRMD states. For example, participants in the highest versus lowest quartile of VPA had lower risks of transitions from baseline to FCRMD (adjusted hazard ratio [aHR] 0.69, 95% confidence interval [CI] 0.64-0.74) and from baseline to death (aHR 0.47, 95% CI 0.39-0.56). In the questionnaire-based cohort, higher PA levels were also associated with lower transition risks (aHRs 0.78-0.93, all P < 0.05). Similar patterns were observed in disease-specific transition analyses. Overall, inverse associations were observed for the onset of FCRMD, subsequent progression to CRMM, and death before established CRMM, whereas associations with mortality after established CRMM were less consistent, particularly in accelerometer-based analyses.
conclusionsHigher PA levels were associated with lower risks across several transitions from baseline or FCRMD states, including the onset of FCRMD, subsequent progression to CRMM, and death before established CRMM. These findings support the relevance of PA promotion and maintenance in strategies addressing CRMM development, while associations with mortality after established CRMM require cautious interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.